Skip to content
Back to Blog
Bio
2026-10-057 min read1

Korea Revises Digital Therapeutics Clinical Trial Protocol Guideline (Sept 10) — Efficacy Endpoints and MCID Specified for Seven Indications, and How SME DTx Developers Should Redesign Trials Ahead of the Year-End Digital-Drug Combination Guidelines

On September 10, Korea's MFDS revised its digital therapeutics clinical trial protocol guideline for seven indications, including nicotine use disorder, depression and ADHD, specifying efficacy endpoints and how to set the MCID. This post covers what SME DTx developers should recheck in their protocols and how to prepare for the digital-drug combination guidelines planned for year-end.

KITIM Consulting Team

What Was Announced — Scope of the September 10 Revision

On September 10, 2026, the National Institute of Food and Drug Safety Evaluation (NIFDS), an agency under Korea's Ministry of Food and Drug Safety (MFDS), revised its Guideline on Preparing Clinical Trial Protocols for Digital Therapeutics. The revision covers seven indications:

  • Nicotine use disorder and alcohol use disorder
  • Panic disorder, depressive disorder and eating disorders
  • Attention-deficit/hyperactivity disorder (ADHD) and mild cognitive impairment
  • Three changes stand out.

  • More specific efficacy criteria: the guideline now reflects current review standards, including evidence-based efficacy endpoints and how to set the minimal clinically important difference (MCID).
  • New operational examples: it adds examples for multi-center trial design and for setting follow-up periods.
  • Updated terminology: items and terms are aligned with the Digital Medical Products Act and its subordinate rules.
  • The guideline is an advisory document for applicants and is not legally binding. Because it reflects protocol reviews accumulated since the Act took effect, it is best read as a guide to what reviewers look for. Unlike guidance on software used by clinicians, this revision concerns clinical design for patient-facing digital therapeutics (DTx).

    Why It Matters — Where DTx Protocols Tend to Be Weak

    The points that draw requests for supplementation in DTx protocols are largely the same.

  • Weak rationale for the primary endpoint: the sponsor cannot explain why that scale and that time point were chosen.
  • No account of clinical meaning: the result is statistically significant, but the protocol does not show that patients would notice the change.
  • Control arm and blinding: whether to use a sham app or standard care, and how to offset the limits of blinding.
  • Dropout and adherence: app-based interventions lose many participants, so the plan for missing data shapes how results are read.
  • Guidance on setting the MCID means the second question now has to be answered at the protocol stage.

    Building Indication-Specific Endpoints and MCID into the Protocol

    Endpoints and assessment timing

    Narrow the primary endpoint to one. If it differs from the examples the guideline gives for your indication, justify the choice with literature. Secondary endpoints should include functional and quality-of-life measures, plus follow-up assessments that show whether the effect lasts after treatment ends.

    MCID, sample size and cost

    The MCID is the starting point for sample size. A simple illustration, assuming a two-arm comparison with two-sided 5% significance and 80% power, shows the stakes.

  • Standardized effect size of 0.5: about 63 per arm, or roughly 158 in total after allowing for 20% dropout
  • Standardized effect size of 0.3: about 174 per arm, or roughly 436 in total after allowing for 20% dropout
  • The enrollment target grows about 2.8 times depending on the assumed effect size. An optimistic assumption leaves the trial underpowered, and a conservative one inflates the budget. That is why the exploratory trial should estimate effect size and dropout, and the confirmatory trial should test against the MCID.

    Pre-defining usage data

    Usage data such as days of access and module completion rates should be defined in the protocol as adherence measures. Criteria set after the fact weaken the credibility of the analysis.

    Expected by Year-End — Three Documents on Digital-Drug Combination Products

    MFDS is working to prepare the following three documents by December. None is final yet, so timing and content may change.

  • A standard operating procedure for integrated review of digital-drug combination products
  • A clinical trial design guideline for digital-drug combination products
  • A clinical trial design guideline for digital medical devices used together with drugs
  • A digital-drug combination product is a drug combined with a digital medical device or a digital medical and health support device, and it requires its own product approval. This can open opportunities for small DTx companies working with pharmaceutical partners. Roles such as who leads clinical design, who owns the data and who is responsible for software change control should be settled at the contract stage.

    A Practical Checklist for SME DTx Developers

  • Confirm whether your indication is one of the seven covered by the revision.
  • Compare the primary endpoint and MCID rationale in any ongoing or planned protocol with the revised guideline.
  • Revisit the effect size and dropout assumptions behind your sample size.
  • If your endpoints or control arm depart from the guideline, use MFDS pre-submission consultation before filing.
  • Design evidence that also serves the steps after approval, including innovative medical technology assessment and health insurance listing.
  • Look for government R&D and support programs that can cover clinical and regulatory costs.
  • How KITIM Can Help

    KITIM connects companies with specialists in digital medical device regulatory strategy and clinical planning, and supports biohealth R&D project planning and proposal writing. If you need a review of your clinical design against the revised guideline or a plan for funding your trial, please request a KITIM consultation. We will work with you to find an approach that fits your stage of development.

    Digital TherapeuticsDTxClinical Trial ProtocolMCIDEfficacy EndpointDigital-Drug Combination ProductDigital Medical Products ActMFDS GuidelinePivotal Trial

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.